Doctor Care Anywhere Buys Into UK Weight Loss Boom for Just A$1.7M
DCA moves into UK weight management with $850,000 MedicSpot acquisition
Doctor Care Anywhere Group PLC (ASX: DOC) entered into a binding asset purchase of the GLP-1 and medicated weight-loss business operated by Outcome Diagnostics Limited (ODL) and MedicSpot on 8 May 2026, paying £850,000 (approximately A$1.7 million) funded entirely from existing cash. The target business generated trailing 12-month revenue of £5.3 million (approximately A$11 million) to March 2026, implying an EV/Sales multiple of 0.16x.
The acquisition is not subject to any material conditions precedent, delivers revenue from day one, and carries no earn-out or deferred consideration. For shareholders, it represents a disciplined, low-cost entry into the fast-growing UK weight management market with no dilution and no shareholder approval required.
When big ASX news breaks, our subscribers know first
What this acquisition brings to DCA
Instant revenue and a proven D2C engine
The MedicSpot/ODL weight management business has been operating since October 2024 and has built a growing active patient base in a competitive digital market. The 11-person team has achieved this with competitive customer acquisition and service costs, demonstrating commercial viability rather than an early-stage concept.
By bringing this team in-house, DCA gains a proven direct-to-consumer (D2C) capability that complements its existing telehealth platform. Revenue contribution begins immediately, with the business broadly breakeven on standalone EBITDA from the outset.
Cross-selling and platform expansion
The 11-person team’s D2C expertise is the primary strategic asset, and management has identified four clear growth levers the acquisition unlocks:
- Expand the existing GLP-1 and weight management business
- Cross-sell weight management services to existing DCA customers
- Accelerate the D2C offer for DCA’s current virtual GP, mental health, physiotherapy, and health assessment products
- Cross-sell DCA’s services to the MedicSpot business’s existing clients
These levers extend well beyond weight management. The acquisition positions DCA to move more aggressively into consumer-facing digital health services across its broader product suite, using the incoming team’s platform and experience as the foundation.
Understanding GLP-1 and the UK weight management opportunity
GLP-1 refers to glucagon-like peptide-1 receptor agonists, a class of medications that includes semaglutide (sold under brand names such as Ozempic and Wegovy). Originally developed to treat type 2 diabetes, these drugs have gained significant mainstream adoption for medicated weight management due to their clinically demonstrated effects on appetite and body weight. Consumer demand in the UK has grown sharply over the past two years, with patients increasingly turning to digital platforms to access prescriptions, consultations, and ongoing monitoring outside of traditional GP settings.
The direct-to-consumer model that ODL and MedicSpot have built is designed specifically to serve this demand. Patients access weight management consultations, prescriptions, and support entirely online, removing the friction of in-person appointments. Telehealth providers like DCA are structurally positioned to serve this market at scale, given their existing technology infrastructure, clinical networks, and regulatory familiarity.
For investors, GLP-1-based weight management represents one of the highest-growth categories in consumer healthcare. DCA’s entry via a low-cost acquisition of an already-operating business with £5.3 million in annual revenue reflects a measured approach to capturing that growth.
CEO Laura O’Riordan
“I am delighted to welcome the Medicspot team to DCA! Both teams are excited by the opportunity to grow faster by collaborating. I know we will focus intently over the coming months on integrating the teams and delivering customer growth we believe can follow from strong execution.”
The next major ASX story will hit our subscribers first
Deal structure and what it means for shareholders
A capital-light deal funded from DCA’s own balance sheet
The transaction economics are straightforward. The table below summarises the key deal metrics as disclosed in the announcement.
| Metric | Detail |
|---|---|
| Purchase price | £850,000 (~A$1.7 million) |
| Funding source | Existing cash balance and positive operating cash flows |
| DCA cash position (31 March 2026) | £7 million (~A$14 million) |
| Revenue (trailing 12 months to March 2026) | £5.3 million (~A$11 million) |
| EV/Sales multiple | 0.16x |
| EBITDA status | Broadly breakeven on standalone EBITDA |
| Earn-out / deferred consideration | None |
Aligned with DCA’s stated growth strategy
This acquisition was not an opportunistic move. Management flagged this type of strategic expansion as part of DCA’s growth plan at the FY2025 results and at the AGM on 28 April 2026, meaning the MedicSpot purchase represents execution against a communicated roadmap.
Chairman John Stier
“Credit to Laura and the DCA executive leadership team for identifying a strategic acceleration opportunity, moving decisively to secure a transaction in the interests of DCA shareholders, and displaying a clear understanding of how to leverage DCA’s strong trading, rehabilitated balance sheet and market leading position to best advantage.”
For shareholders, the deal terms are notably straightforward and capital-efficient:
- No shareholder approval required under ASX Listing Rules
- No related-party involvement
- No earn-out or deferred consideration
- Fully funded from existing cash and positive operating cash flows
- Transaction not subject to material conditions precedent
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, with in-depth analysis already done. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.